NYSE:ALUR
ALLURION TECHNOLOGIES, INC.
A minimally invasive obesity treatment company developing proprietary endoscopic devices with improving operational efficiency despite recent revenue contraction.
Key Metrics
Investment Thesis
Bull Case
The narrowing net loss demonstrates that the company is making meaningful progress toward sustainable profitability, potentially signaling a turning point in its commercialization efforts. Investors may view the current valuation as attractive given the company's unique technology and the potential for future product launches to drive growth. The shift from an $80.6M loss to a $26.1M loss suggests that recent operational strategies are yielding positive financial results.
Bear Case
The drastic 40% drop in revenue combined with negative operating cash flow of -$42.3M indicates severe commercial challenges and potential product-market fit issues. With shareholders' equity remaining deeply negative at -$78.0M, the company faces significant hurdles in funding operations without further dilution or debt restructuring. The large long-term debt obligation of $35.7M poses a solvency risk if revenue growth does not accelerate rapidly.
About ALLURION TECHNOLOGIES, INC.
Allurion Technologies focuses on developing minimally invasive obesity treatment solutions, primarily through its proprietary ALLURION endoscopic device. The company serves the global healthcare market with a pipeline of innovative weight management technologies aimed at reducing reliance on bariatric surgery. Recent financials show a shift towards profitability as revenue decreased significantly from $53.5M in 2023 to $32.1M in 2024, while net loss narrowed to -$26.1M.
Analysis
Management Discussion
Management successfully narrowed the net loss from -$80.6M in 2023 to -$26.1M in 2024, indicating improved cost controls or operational efficiency. However, the substantial reduction in revenue from $53.5M to $32.1M requires urgent attention as it likely contributed to a negative operating cash flow of -$42.3M. The company remains heavily reliant on equity financing given its total liabilities of $110.8M against only $15.7M in cash.
Industry Overview
The medical device industry for obesity treatment is experiencing rapid innovation with a shift towards less invasive procedures and digital health integration. Competition is intensifying as traditional surgical methods face pressure from new endoscopic technologies that offer faster recovery times and lower complication rates. Regulatory approval processes remain rigorous but provide long-term protection for established players who have successfully navigated clinical trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $53.5M | $32.1M |
| Cost of Revenue | $12.0M | $10.6M |
| Gross Profit | $41.5M | $21.5M |
| Operating Expenses | $120.6M | $71.7M |
| Operating Income | $-79.1M | $-50.2M |
| R&D | $27.7M | $17.4M |
| G&A | $46.0M | $28.4M |
| Marketing | $46.9M | $25.9M |
| Stock-Based Comp | $8.4M | $3.1M |
| D&A | $746.0K | $997.0K |
| Depreciation | $746.0K | $1.0M |
| Other OpEx | $0 | $0 |
| Non-Operating Income | $-1.3M | $24.8M |
| Interest Expense | $10.6M | — |
| Pre-Tax Income | $-80.3M | $-25.4M |
| Income Tax | $264.0K | $718.0K |
| Continuing Ops | $-80.6M | $-26.1M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-80.6M | $-26.1M |
| Minority Interest | $0 | $0 |
| Net to Common | $-80.6M | $-26.1M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $64.8M | $27.2M |
| Cash & Equivalents | $38.0M | $15.4M |
| Accounts Receivable | $18.2M | $7.1M |
| Inventory | $6.2M | $3.4M |
| Prepaid Expenses | $2.4M | $1.2M |
| Other Current Assets | $0 | $0 |
| Long-Term Assets | $6.9M | $5.7M |
| PP&E (Net) | $3.4M | $2.5M |
| Operating Leases | $3.0M | $2.1M |
| Other LT Assets | $505.0K | $1.1M |
| Total Assets | $71.7M | $32.8M |
| Current Liabilities | $65.4M | $18.9M |
| Accounts Payable | $10.4M | $6.6M |
| Current Debt | $38.6M | — |
| Current Leases | $908.0K | $869.0K |
| Other Current Liab | $15.5M | $11.4M |
| Long-Term Liabilities | $76.8M | $91.9M |
| Long-Term Debt | — | $35.7M |
| LT Operating Leases | $2.3M | $1.3M |
| Other LT Liab | $74.5M | $54.9M |
| Total Liabilities | $142.2M | $110.8M |
| Shareholders' Equity | $-70.5M | $-78.0M |
| Paid-In Capital | $143.0M | $152.6M |
| Retained Earnings | $-212.8M | $-238.9M |
| AOCI | $-700.0K | $8.4M |
| Total L&E | $71.7M | $32.8M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-80.6M | $-26.1M |
| Non-Cash Adjustments | $7.0M | $3.1M |
| Working Capital Changes | $9.7M | $-19.3M |
| Cash from Operations | $-64.0M | $-42.3M |
| Capital Expenditures | $1.6M | $611.0K |
| Cash from Investing | $-1.6M | $-611.0K |
| Cash from Financing | $96.0M | $20.2M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $30.4M | $-22.7M |
| Beginning Cash | $8.0M | $38.4M |
| Ending Cash | $38.4M | $15.7M |
Frequently Asked Questions
How does ALLURION TECHNOLOGIES, INC. make money?
Device sales and licensing of the ALLURION system; Clinical services and related medical support; Intellectual property royalties from strategic partnerships.
What are the main risks for ALUR?
Significant revenue decline of 40% year-over-year suggesting market saturation or competitive pressure; Persistent negative operating cash flow of -$42.3M raising liquidity concerns; High accumulated deficit of -$238.9M impacting balance sheet stability and dilution risk.
What is ALUR's competitive advantage?
Proprietary endoscopic technology offering a less invasive alternative to traditional gastric bypass surgery; Strong regulatory clearance in key markets providing barriers to entry; Growing global footprint with established clinical data supporting efficacy.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.